Raia DrogasilBSP:RADL3 +0.70%91 EBITDA Margin % is 9.35% as of Mar. 2026, which is 13% above its 10-year median of 8.26. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Raia Drogasil ranks worse than 53.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Raia Drogasil's EBITDA for the
three
months ended in Mar. 2026 was R$988 Mil. Raia Drogasil's Revenue for the
three
months ended in Mar. 2026 was R$10,569 Mil. Therefore, Raia Drogasil's EBITDA margin for the quarter that ended in Mar. 2026 was 9.35%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Raia Drogasil EBITDA Margin % Related Terms
Raia Drogasil EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a EBITDA Margin % of 9.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Raia Drogasil and its competitors. This is 13% above median its historical median of 8.26. Over the past decade, Raia Drogasil's EBITDA Margin % has ranged from 7.51 to 12.04. According to the industry distribution chart, Raia Drogasil ranks #356 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 53.3%.
Is Raia Drogasil's EBITDA Margin % too high?
Raia Drogasil's current EBITDA Margin % of 9.35% is 13% above median its 10-year median of 8.26. Over the past 10 years, this metric has ranged from a low of 7.51 to a high of 12.04. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Raia Drogasil's value of 9.35% is 8.4% below this industry median. Based on the distribution chart, Raia Drogasil ranks #356 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #356 out of 668 companies for EBITDA Margin %. This places Raia Drogasil in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Raia Drogasil's value of 9.35% is 8.4% below this benchmark. Historically, Raia Drogasil's own EBITDA Margin % has ranged from 7.51 to 12.04 over the past decade. While the company's 10-year median is 8.26 vs. the industry median of 10.21, Raia Drogasil has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current EBITDA Margin % of 9.35% is 8.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current EBITDA Margin % is 9.35%, which is 13% above median its own 10-year median of 8.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.94, compared to a current price of R$17.20 — trading 42.6% below its estimated fair value. The current EBITDA Margin % is 9.35%, which is 13% above median its 10-year median of 8.26 and 8.4% below the Healthcare Providers & Services industry median of 10.21. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current EBITDA Margin % is 9.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$17.20 is trading 42.6% below its estimated GF Value™ of R$29.94.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
EBITDA Margin %: 9.35% (13% above median its 10-year median of 8.26)
GF Value™: R$29.94 vs. price of R$17.20 (42.6% below fair value)
Industry Position: 8.4% below the Healthcare Providers & Services median (#356 of 668)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
